Technical Analysis for GLTO - Galecto, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -1.53% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -1.53% |
| Alert | Time |
|---|---|
| Jack-in-the-Box Bearish Entry | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| Down 1% | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/04/2024
Galecto, Inc. Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Breakthrough Therapy Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Progressive Fibrosis mTOR Fibrotic Disease Lectins Lung Diseases Copenhagen Galectin Myelofibrosis Treatment Of Fibrosis Galectin 3 Galecto Biotech
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.5 |
| 52 Week Low | 5.622 |
| Average Volume | 33,550 |
| 200-Day Moving Average | 13.86 |
| 50-Day Moving Average | 8.82 |
| 20-Day Moving Average | 6.83 |
| 10-Day Moving Average | 6.63 |
| Average True Range | 0.46 |
| RSI (14) | 25.37 |
| ADX | 39.76 |
| +DI | 9.48 |
| -DI | 35.14 |
| Chandelier Exit (Long, 3 ATRs) | 6.20 |
| Chandelier Exit (Short, 3 ATRs) | 7.02 |
| Upper Bollinger Bands | 7.73 |
| Lower Bollinger Band | 5.94 |
| Percent B (%b) | -0.07 |
| BandWidth | 26.23 |
| MACD Line | -0.65 |
| MACD Signal Line | -0.66 |
| MACD Histogram | 0.0173 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.19 | ||||
| Resistance 3 (R3) | 6.21 | 6.12 | 6.12 | ||
| Resistance 2 (R2) | 6.12 | 6.02 | 6.10 | 6.10 | |
| Resistance 1 (R1) | 5.96 | 5.96 | 5.92 | 5.94 | 6.08 |
| Pivot Point | 5.87 | 5.87 | 5.84 | 5.85 | 5.87 |
| Support 1 (S1) | 5.71 | 5.77 | 5.67 | 5.69 | 5.54 |
| Support 2 (S2) | 5.62 | 5.71 | 5.60 | 5.52 | |
| Support 3 (S3) | 5.46 | 5.62 | 5.50 | ||
| Support 4 (S4) | 5.44 |
